Adial Pharmaceuticals Inc. | William Stilley, CEO of Adial Pharmaceuticals (NASDAQ: ADIL) sits down with BAF host Michelle Griego to discuss the company’s lead asset, AD04, as a potential genetically targeted treatment for alcohol and opioid use disorder.
16292
post-template-default,single,single-post,postid-16292,single-format-link,ajax_fade,page_not_loaded,,qode-theme-ver-16.2.1,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.7,vc_responsive

William Stilley, CEO of Adial Pharmaceuticals (NASDAQ: ADIL) sits down with BAF host Michelle Griego to discuss the company’s lead asset, AD04, as a potential genetically targeted treatment for alcohol and opioid use disorder.